Doxycycline post-exposure prophylaxis (Doxy-PEP) in Czech clinical practice: a review of efficacy, safety, and implications for antimicrobial resistance

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F44555601%3A13450%2F25%3A43899765" target="_blank" >RIV/44555601:13450/25:43899765 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.researchgate.net/publication/400252564_Doxycycline_post-exposure_prophylaxis_Doxy-PEP_in_Czech_clinical_practice_a_review_of_efficacy_safety_and_implications_for_antimicrobial_resistance" target="_blank" >https://www.researchgate.net/publication/400252564_Doxycycline_post-exposure_prophylaxis_Doxy-PEP_in_Czech_clinical_practice_a_review_of_efficacy_safety_and_implications_for_antimicrobial_resistance</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Doxycycline post-exposure prophylaxis (Doxy-PEP) in Czech clinical practice: a review of efficacy, safety, and implications for antimicrobial resistance

Popis výsledku v původním jazyce

Doxycycline post-exposure prophylaxis (Doxy-PEP; a single 200 mg dose of doxycycline within 72 hours after sexual exposure, not exceeding 200 mg per 24 hours) has been shown in randomized trials among men who have sex with men (MSM) and transgender women (TGW) to reduce the incidence of syphilis and Chlamydia trachomatis infection; its effect on Neisseria gonorrhoeae transmission is smaller and varies by locale. In 2024, the U.S. Centers for Disease Control and Prevention (CDC) published the first clinical guidance recommending targeted use of Doxy-PEP for MSM/TGW with a bacterial sexually transmitted infection (STI) in the previous 12 months; European branch of International Union Against Sexually Transmitted Infectuions (IUSTI-Europe) in June 2024 acknowledged individual benefits while urging caution; and in 2025 the World Health Organization initiated development of global guidance. To provide a clinically oriented review of the effectiveness, safety, and risks of Doxy-PEP and to place these findings within the Czech context of epidemiology and antimicrobial resistance, including interpretation of the national position statement of the Society for Infectious Medicine (SIL ČLS JEP). Doxy-PEP is an effective tool for preventing syphilis and Chlamydia trachomatis infection in high-risk MSM/TGW. Given potential adverse effects, the risk of antimicrobial resistance (AMR) development, and the still limited data for other populations, cautious, data-driven use within comprehensive sexual health care is advisable. This approach is consistent with international recommendations and the current SIL ČLS JEP position statement.

Název v anglickém jazyce

Doxycycline post-exposure prophylaxis (Doxy-PEP) in Czech clinical practice: a review of efficacy, safety, and implications for antimicrobial resistance

Popis výsledku anglicky

Doxycycline post-exposure prophylaxis (Doxy-PEP; a single 200 mg dose of doxycycline within 72 hours after sexual exposure, not exceeding 200 mg per 24 hours) has been shown in randomized trials among men who have sex with men (MSM) and transgender women (TGW) to reduce the incidence of syphilis and Chlamydia trachomatis infection; its effect on Neisseria gonorrhoeae transmission is smaller and varies by locale. In 2024, the U.S. Centers for Disease Control and Prevention (CDC) published the first clinical guidance recommending targeted use of Doxy-PEP for MSM/TGW with a bacterial sexually transmitted infection (STI) in the previous 12 months; European branch of International Union Against Sexually Transmitted Infectuions (IUSTI-Europe) in June 2024 acknowledged individual benefits while urging caution; and in 2025 the World Health Organization initiated development of global guidance. To provide a clinically oriented review of the effectiveness, safety, and risks of Doxy-PEP and to place these findings within the Czech context of epidemiology and antimicrobial resistance, including interpretation of the national position statement of the Society for Infectious Medicine (SIL ČLS JEP). Doxy-PEP is an effective tool for preventing syphilis and Chlamydia trachomatis infection in high-risk MSM/TGW. Given potential adverse effects, the risk of antimicrobial resistance (AMR) development, and the still limited data for other populations, cautious, data-driven use within comprehensive sexual health care is advisable. This approach is consistent with international recommendations and the current SIL ČLS JEP position statement.

Druh

J_ost - Ostatní články v recenzovaných periodicích

CEP obor

—

OECD FORD obor

30216 - Dermatology and venereal diseases

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Časopis lékařů českých

ISSN

0008-7335

e-ISSN

—

Svazek periodika

164

Číslo periodika v rámci svazku

7-8

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

5

Strana od-do

311-315

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—